See more : Emmerson PLC (EML.L) Income Statement Analysis – Financial Results
Complete financial analysis of AgeX Therapeutics, Inc. (AGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AgeX Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aspen Technology, Inc. (AZPN) Income Statement Analysis – Financial Results
- Enwell Energy plc (ENW.L) Income Statement Analysis – Financial Results
- Triple Point Social Housing REIT plc (SOHO.L) Income Statement Analysis – Financial Results
- Bangkok Expressway and Metro Public Company Limited (BKKXF) Income Statement Analysis – Financial Results
- Peet Limited (PPC.AX) Income Statement Analysis – Financial Results
AgeX Therapeutics, Inc. (AGE)
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 142.00K | 34.00K | 144.00K | 1.87M | 1.73M | 1.40M | 1.40M |
| Cost of Revenue | 171.00K | 13.00K | 19.00K | 158.00K | 244.00K | 364.00K | 168.00K |
| Gross Profit | -29.00K | 21.00K | 125.00K | 1.71M | 1.48M | 1.03M | 1.24M |
| Gross Profit Ratio | -20.42% | 61.76% | 86.81% | 91.54% | 85.88% | 73.93% | 88.03% |
| Research & Development | 603.00K | 1.03M | 1.46M | 4.98M | 5.90M | 6.63M | 5.78M |
| General & Administrative | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.33M | 5.97M | 6.71M | 7.40M | 8.14M | 5.65M | 3.87M |
| Other Expenses | 11.00K | 13.00K | 448.00K | 44.00K | 294.00K | 183.00K | 38.00K |
| Operating Expenses | 9.93M | 7.00M | 8.16M | 12.38M | 14.04M | 12.28M | 9.65M |
| Cost & Expenses | 10.10M | 7.01M | 8.18M | 12.54M | 14.29M | 12.64M | 9.82M |
| Interest Income | 0.00 | 3.34M | 1.10M | 404.00K | 29.00K | 0.00 | 0.00 |
| Interest Expense | 4.90M | 3.34M | 1.10M | 0.00 | 0.00 | 116.00K | 0.00 |
| Depreciation & Amortization | 131.00K | 145.00K | 579.00K | 1.68M | 951.00K | 535.00K | 682.00K |
| EBITDA | -9.83M | -6.98M | -7.93M | -9.15M | -11.61M | -10.71M | -9.49M |
| EBITDA Ratio | -6,921.83% | -20,088.24% | -5,180.56% | -481.21% | -671.76% | -767.19% | -675.85% |
| Operating Income | -9.96M | -6.98M | -8.04M | -10.67M | -12.56M | -11.25M | -6.66M |
| Operating Income Ratio | -7,014.08% | -20,514.71% | -5,582.64% | -571.25% | -726.79% | -805.52% | -474.57% |
| Total Other Income/Expenses | -4.85M | -3.55M | -649.00K | 272.00K | 323.00K | 3.51M | 1.78M |
| Income Before Tax | -14.81M | -10.52M | -8.58M | -11.13M | -12.24M | -7.73M | -6.64M |
| Income Before Tax Ratio | -10,430.28% | -30,947.06% | -5,959.72% | -595.61% | -708.10% | -553.80% | -472.72% |
| Income Tax Expense | -8.00K | 152.00K | 1.64M | -150.00K | 148.00K | 3.51M | -1.80M |
| Net Income | -14.80M | -10.67M | -10.22M | -10.98M | -12.38M | -7.50M | -6.58M |
| Net Income Ratio | -10,424.65% | -31,394.12% | -7,097.22% | -587.58% | -716.67% | -537.39% | -468.66% |
| EPS | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted | -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| Weighted Avg Shares Out | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.08M | 1.08M | 1.08M | 1.07M | 1.06M | 992.72K | 1.02M |
Relaxation In ITR Verification: Here Is All You Should Know
Is your ITR from last five years still incomplete? Here is your chance to do it
ITR filing: 5 things to know about new rule for verification of old ITRs
Taxpayers asked to verify ITRs for AYs 2015-16 to 2019-20 by September 30
I-T Dept Asks Taxpayers to Verify E-filed Tax Returns for Assessment Years 2015-16 to 2019-20 by Sept 30
TDS levy on cash withdrawal of over Rs 20 lakh from bank account if you haven't done this
Here's how banks will find out if you have filed last 3 years income tax returns
ITR Filing FY 19-20: Key dates and things to remember
New TDS rules: How much tax is deducted for making cash withdrawals from bank
Can I claim HRA tax exemption for rent paid to spouse while filing ITR?
Source: https://incomestatements.info
Category: Stock Reports